| 2026-03-20 |
股东大会：
将于2026-05-01召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ five nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To approve the adoption of an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock.
4.To approve the adoption of an amendment to our Certificate of Incorporation, as amended, to revise the voting threshold required for an increase or decrease of Common Stock.
5.To ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. (“CBIZ”) as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
6.To approve the adjournment of the Annual Meeting in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of Proposal 3 is insufficient.
7.To conduct any other business properly brought before the meeting.
|
| 2026-03-18 |
详情>>
业绩披露：
2025年年报每股收益-0.79美元,归母净利润-1216.36万美元,同比去年增长-13.35%
|
| 2025-11-13 |
详情>>
股本变动：
变动后总股本1667.31万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.75美元,归母净利润-1046.04万美元,同比去年增长-51.74%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.67美元,归母净利润-846.17万美元,同比去年增长-84.53%
|
| 2025-07-17 |
复牌提示：
2025-07-17 10:21:59 停牌，复牌日期 2025-07-17 10:26:59
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.4美元,归母净利润-444.62万美元,同比去年增长-85.81%
|
| 2025-04-24 |
股东大会：
将于2025-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ four nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
4.To conduct any other business properly brought before the meeting.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-1.19美元,归母净利润-1073.13万美元,同比去年增长-30.28%
|
| 2025-02-04 |
股东大会：
将于2025-03-21召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of the shares issuable upon exercise of (i) Series A Warrants to acquire 5,031,250 shares of Common Stock (the “Private Placement Warrants”) and (ii) Series B Warrants to acquire 3,247,445 shares of Common Stock (the “Pre-Funded Warrants”, and together with the Private Placement Warrants, the “Warrants”).
2.To conduct any other business properly brought before the meeting.
|
| 2024-12-23 |
详情>>
内部人交易：
New Enterprise Associates 16, L.P.股份增加554250.00股
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.77美元,归母净利润-689.37万美元,同比去年增长-26.87%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.51美元,归母净利润-458.55万美元,同比去年增长-87.03%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.27美元,归母净利润-239.28万美元,同比去年增长51.83%
|
| 2024-04-26 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ five nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
4.To conduct any other business properly brought before the meeting.
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-0.94美元,归母净利润-823.68万美元,同比去年增长72.48%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.62美元,归母净利润-543.37万美元,同比去年增长79.16%
|
| 2023-04-28 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ five nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To indicate, on an advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers.
4.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
5.To conduct any other business properly brought before the meeting.
|
| 2023-01-27 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-04-15 |
股东大会：
将于2022-05-24召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ seven nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To approve an amendment to the Company’s Certificate of Incorporation to increase the authorized number of shares of common stock from 150,000,000 shares to 300,000,000 shares.
4.To approve a series of alternate amendments to the Company’s Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from one-for-three (1:3) to one-for-twelve (1:12), inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors prior to the date of the 2023 Annual Meeting of Stockholders.
5.To approve a series of alternate amendments to the Company’s Certificate of Incorporation to effect, if and only if Proposal 4 is both approved and implemented, a reduction in the total number of authorized shares of the Company’s common stock as illustrated in the table under the caption “Effects of Authorized Shares Reduction” in the section of the accompanying proxy statement entitled “Approval of Reduction in the Number of Authorized Shares of Common Stock.”
6.To approve the Company’s 2020 Equity Incentive Plan, as amended, to increase the number of shares authorized for issuance by 8,500,000 shares.
7.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.
8.To conduct any other business properly brought before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-12 |
财报披露：
美东时间 2021-05-12 盘后发布财报
|
| 2021-04-23 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s seven nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
4.To conduct any other business properly brought before the meeting.
|
| 2020-04-17 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s seven nominees for director to hold office until the next Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
3.To ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
4.To approve the Company’s 2020 Equity Incentive Plan.
5.To conduct any other business properly brought before the meeting.
|
| 2019-03-28 |
股东大会：
将于2019-05-09召开股东大会
会议内容 ▼▲
- 1.To elect six (6) Directors of the Company to serve until the next annual meeting of stockholders;
2.To approve by a non-binding advisory vote the executive compensation of our named executive officers;
3.To ratify the appointment of Marcum LLP as the Company’s independent auditors for the year ending December 31, 2019;
4.To transact such other business as may properly come before the Annual Meeting and any postponements or adjournments thereof.
|
| 2018-09-14 |
股东大会：
将于2018-10-16召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of TapImmune common stock, warrants to purchase TapImmune common stock and the issuance of shares of TapImmune common stock issuable upon exercise of warrants to purchase TapImmune common stock, in each case, pursuant to the merger agreement.
2.To approve the issuance of TapImmune common stock, warrants to purchase TapImmune common stock and the issuance of shares of TapImmune common stock issuable upon exercise of warrants to purchase TapImmune common stock, in each case, pursuant to the private placement transaction.
3.To approve two separate proposals to amend TapImmune’s articles of incorporation to:
a.increase the number of authorized shares of TapImmune common stock from 41,666,667 to 150,000,000, the approval of which is necessary to enable TapImmune to issue the required number of shares of TapImmune common stock, and shares of TapImmune common stock issuable upon exercise of warrants, in each case, to Marker stockholders in connection with the merger and to the investors in the private placement transaction;
b.change the name of TapImmune to “Marker Therapeutics, Inc.”
4.To approve the reincorporation of TapImmune from a Nevada corporation to a Delaware corporation.
5.To approve an increase in the number of authorized shares of TapImmune common stock reserved for issuance under the TapImmune Plan by 6,616,666 shares from 1,383,334 to 8,000,000 shares upon completion of the merger.
6.To elect seven persons as directors of TapImmune; provided, however, that if the merger is completed, the board of directors of TapImmune will be reconstituted as set forth in the merger agreement.
7.To approve on a non-binding advisory basis TapImmune’s 2017 executive compensation.
8.To ratify the appointment of Marcum LLP as TapImmune’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
9.To consider and vote on a proposal to adjourn the 2018 Annual Meeting, if necessary, if a quorum is present, to solicit additional proxies, in the event that there are not sufficient votes at the time of the 2018 Annual Meeting to approve items 1, 2, 3a, 3b, 4, or 5 above.
10.To transact such other business as may properly come before the 2018 Annual Meeting or any adjournment or postponement thereof.
|
| 2017-07-12 |
股东大会：
将于2017-08-29召开股东大会
会议内容 ▼▲
- 1.To elect six (6) Directors of the Company to serve until the next annual meeting of stockholders;
2.To conduct a non-binding advisory vote on executive compensation;
3.To conduct a non-binding advisory vote on the desired frequency of a non-binding advisory vote on executive compensation;
4.To approve the Company’s 2014 Omnibus Stock Ownership Plan, as Amended Through July 2017;
5.To approve an amendment to the Company’s 2014 Omnibus Stock Ownership Plan to increase the authorized shares by 800,000;
6.To ratify the appointment of Marcum LLP as the Company’s independent auditors for the year ending December 31, 2017;
7.To transact such other business as may properly come before the Annual Meeting and any postponements or adjournments thereof.
|